bioAffinity Technologies Inc. (BIAF)
BIAF trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.63
-7.05% on the day
Market cap
$4.7M
Nano cap
Revenue · 2025
$6.2M
-34.2% on 2024
Net income · 2025
-$14.9M
-242.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | BIAF on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001712762 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6.2M |
| Net income | -$14.9M |
| Operating income | -$10.6M |
| Net margin | -242.0% |
| Operating margin | -171.6% |
| Revenue growth | -34.2% |
| Cash | $6.4M |
| Total assets | $11.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-09 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-08-07 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | PRE 14A | 2026-09-29 |
Source: SEC EDGAR submissions feed, 394 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BIAFW | bioAffinity Technologies Inc. Warrant | $0.3000 |
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ISPC | iSpecimen Inc. | $1.08 | 0.00% | $2.7M |
| ONMD | OneMedNet Corp | $4.02 | +2.29% | $24.2M |
| MXCT | MaxCyte Inc. | $0.9643 | -3.08% | $99.5M |
| NRC | NRC Health | $20.17 | -1.18% | $446.2M |
| OABI | OmniAb Inc. | $4.70 | -1.47% | $683.3M |
| ABSI | Absci Corporation | $9.10 | -5.89% | $1.6B |
| ICLR | ICON plc | $164.34 | -0.04% | $12.6B |
| CRL | Charles River Laboratories International Inc. | $299.02 | -0.94% | $14.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier